Gastrointestinal stromal tumors (GISTs) are the most common of the mesenchymal tumors, which probably arise from the interstitial cells of Cajal[@b1]. One of the most prominent characteristics of GISTs is the malignant potential that ranges from a benign behavior to aggressive sarcomas. To evaluate the malignant potential of GISTs, some criteria were established as determined by tumor size, location and number of mitoses, such as NIH criteria[@b2], modified NIH criteria[@b3] and AFIP criteria[@b4]. However, increasing evidence show that some other factors, for example sex[@b5], genotype[@b6][@b7], immune infiltrates[@b8], as well as positive surgical margins[@b9][@b10], could play an important role in the prognosis of GISTs.

It is a general consensus that surgical excision is the definitive treatment for primary GISTs without peritoneal seeding or metastasis. The goal of surgical treatment is complete gross resection with an intact pseudocapsule and negative microscopic margins (R0), according to the ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) guidelines[@b11][@b12]. Notably, apart from three central parameters (tumor size, number of mitosis and tumor location), two additional prognostic factors (surgical margins and tumor rupture) were added in the 2012 edition of ESMO guideline[@b13]. However, surgical margins were removed in the 2014 edition[@b11], on the basis of some emerging evidence. In a prospective randomized series, the majority of patients with an R1 resection did not experience a recurrence in absence of tumor rupture and there was no statistically significant difference in recurrence rate compared with R0 resection[@b14]. Therefore, given that GISTs often abut some vital structures such as gastroesophageal junction, duodenal papilla as well as retroperitoneal vessels, R1 margins are acceptable especially for low-risk lesions when R0 resection might imply major functional sequelae[@b11][@b14]. However, other reports support positive microscopic margins (R1) as a main prognostic factor of tumor recurrence[@b15][@b16].

These controversial results present challenges to the therapeutic strategies after R1 surgery. The management of R1 resection still remains undefined. The NCCN guideline reported no evidence of a need for re-excision, while the ESMO guideline suggested that re-excision may be an option on the condition that the original site of margins can be found and major functional sequelae are not foreseen. Therefore, it is necessary to perform a systematic and comprehensive meta-analysis to validate the prognostic value of surgical margins and the clinical impact of R1 resection.

In this study, we sought to conduct a meta-analysis to estimate the prognostic value of surgical margins for disease-free survival (DFS) and overall survival (OS) in patients with primary GISTs. In addition, we also comprehensively appraised the quality of evidence and recommended the evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE) to facilitate clinical decision-making.

Results
=======

Study selection and characteristics
-----------------------------------

The initial and updated searches together identified 427 records. Upon further review, 19 articles evaluating the prognostic value of surgical margins in patients with primary GISTs were considered eligible. Of the 19 articles, 2 were excluded due to the insufficient reported data for the estimation of HR, 3 were excluded because they put R1 resection and R2 resection together, and 2 were excluded due to the small sample size (there are only 2 cases with R1 margin in both studies)[@b17][@b18]. Finally, a total of 12 studies[@b14][@b15][@b16][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27] were included in this meta-analysis. Literatures screening process was shown in [Fig. 1](#f1){ref-type="fig"}.

The characteristics of included studies are shown in [Table 1](#t1){ref-type="table"}. In total, 12 studies including 1985 patients were included in the pooled analysis. DFS was obtained in 11 studies, and OS was obtained in 8 studies. All studies had minimum 5 years follow-up period. The rate of R1 resection ranges from 3.5--33.3% (pooled rate 11.9%, 95% CI 8.3--15.4%). Adjuvant imatinib treatment was given in 5 of the studies. The quality of study assessed by Newcastle-Ottawa quality assessment scale ranged from seven to eight, with high value indicating eligible methodology ([Table S1](#S1){ref-type="supplementary-material"}).

Recurrence rate
---------------

The overall recurrence rate in R1 resection and R0 resection group was 0.364 (95% CI 0.299--0.429) and 0.296 (95% CI 0.161--0.430), respectively. Although the recurrence rate in R1 resection group was slightly higher than that in R0 resection group, meta-analysis revealed that R1 resection did not increase the recurrence rate of GISTs (OR by fixed-effects model 0.891, 95% CI 0.653--1.215; OR by random-effects model 1.203, 95% CI 0.632--2.287; I^2^ = 66.2%, P value = 0.003) ([Fig. 2](#f2){ref-type="fig"}). To explore the source of heterogeneity, meta-regression and subgroup analysis were performed. Adjuvant imatinib treatment was not the source of heterogeneity ([Table 2](#t2){ref-type="table"}). Sensitivity analysis indicated that pooled ORs were not significantly influenced by omission of any single study.

Disease-free survival
---------------------

Meta-analysis using a random-effects model indicated that R1 resection had an unfavorable DFS compared with R0 resection (HR 1.596, 95% CI 1.128--2.258; I^2^ = 37.5%, P value = 0.091), which was consistent with the results of the fixed-effects model (HR 1.567, 95% CI 1.246--1.969) ([Fig. 3](#f3){ref-type="fig"}). To determine whether other factors had an influence on the HR of DFS, we carried out subgroup analysis and meta-regression analysis. [Table 3](#t3){ref-type="table"} demonstrates the overall and stratified analysis. Notably, in the adjuvant imatinib treatment subgroup, the patients with R1 resection showed no significant difference of DFS compared with R0 resection (HR 1.308, 95% CI 0.583--2.935; I^2^ = 53.2%, P value = 0.074). In the subgroup without adjuvant imatinib treatment, DFS of R1 resection still remained poor (HR 1.758, 95% CI 1.338--2.310; I^2^ = 11.3%, P value = 0.343). These results indicate that adjuvant imatinib treatment could attenuate the risk of recurrence for primary GIST patients who received R1 resection. Sensitivity analysis indicated that pooled HR was not significantly influenced by omission of any single study.

Overall survival
----------------

Eight studies including 553 GIST patients assessed overall survival ([Table 4](#t4){ref-type="table"}). Although R1 resection showed a tendency of poor OS, it failed to get a statistically significant HR (HR by fixed-effects model 1.283, 95% CI 0.770--2.138; HR by random-effects model 1.430, 95% CI 0.608--3.363; I^2^ = 60.8%, P value = 0.013) ([Fig. 4](#f4){ref-type="fig"}). When stratified by adjuvant imatinib treatment, there was no significant difference between R1 resection and R0 resection in adjuvant imatinib treatment subgroup (HR 1.232, 95% CI 0.185--8.204; I^2^ = 73.8%, P value = 0.01), or in subgroup without adjuvant treatment (HR 1.755, 95% CI 0.947--3.254; I^2^ = 8.4%, P value = 0.351). Sensitivity analysis indicated that pooled HR was not significantly influenced by omitting any single study.

Publication bias
----------------

No evidence of publication bias was detected by either Begg's or Egger's test for OR of recurrence (Begg's P = 1.000, Egger's P = 0.197), HR of DFS (Begg's P = 0.891, Egger's P = 0.986), or HR of OS (Begg's P = 0.322, Egger's P = 0.350). The shape of the funnel plots did not reveal obvious asymmetry ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}).

Quality of evidence
-------------------

This meta-analysis contained three outcomes: recurrence rate, disease-free survival and overall survival. The GRADE system evidence for each outcome level and reasons for upgrade and downgrade are shown in [Table 5](#t5){ref-type="table"}.

Discussion
==========

Due to insights in the molecular targeted therapy and improved surgical techniques, treatment of GISTs has developed rapidly. Unpredictable malignant potential and rare lymph node metastasis provided the theoretical basis for the concept of minimally invasive surgery for GISTs. Consequently, several minimally invasive surgical approaches have been introduced, such as local wedge excision, laparoscopic surgery, endoscopic enucleation and related variations of this technique. However, there is a fine balance between complete resection and minimally invasive resection. Sometimes, an R1 resection might be inescapable owing to the following reasons. First, as a neoplasm arising from the mesenchymal tissue, GIST often abuts significant vessels and other vital structures. Thus, to avoid major functional sequelae, organ-preserving surgery is acceptable with a close or microscopically positive margin. Second, DeMatteo *et al.*[@b27] suggested that large GISTs that infiltrated the serosa of the bowel wall, might shed cells from anywhere along their surface into the peritoneum. This theory was also supported by the study of Crosby *et al.*[@b28]. Third, with increasing upper gastrointestinal examination by endoscopy, the incidence of subclinical GIST has been higher than anticipated[@b29]. These incidentally encountered GISTs are often treated by endoscopic enucleation. However, Tumor enucleation is considered insufficient, given that it may leave behind a tumor-seeded pseudocapsule with R1 resection[@b1][@b30]. Even though some innovative endoscopic procedures attempte to support enucleation, such as endoscopic full-thickness resection (EFTR)[@b31], laparoscopy endoscopy cooperative surgery (LECS)[@b32], laparoscopy-assisted endoscopic full-thickness resection (LAEFR)[@b33], and non-exposed wall-inversion surgery (NEWS)[@b34], the efficacy and safety of those procedures are still assessed in the clinical trials. Fourth, the surgical safe margins are not well defined for GISTs. Most reports indicated that the 1--2 cm margins including the 5 mm of microscopic distance might be adequate in GISTs[@b35][@b36]. But the guidelines are not conclusive.

This meta-analysis included 12 studies with 1985 surgically treated primary GIST patients. The overall recurrence rate in R1 resection and R0 resection group was 0.364 (95% CI 0.299--0.429) and 0.296 (95% CI 0.161--0.430), respectively. Although some of these studies found that macroscopic tumor-free margins are essential to a good outcome of GIST surgery, but whether the status of microscopic margins could impact the recurrence remains unclear. The pooled results from this meta-analysis confirmed that a microscopically positive margin could significantly impact the disease-free survival (HR 1.596, 95% CI 1.128--2.258; I^2^ = 37.5%, P value = 0.091), but had no influence on overall survival (HR 1.430, 95% CI 0.608--3.363; I^2^ = 60.8%, P value = 0.013). Importantly, subgroup analysis revealed that there was no significant difference of DFS between R1 resection and R0 resection in the era of adjuvant imatinib treatment (HR 1.308, 95% CI 0.583--2.935; I^2^ = 53.2%, P value = 0.074), however, in the subgroup without adjuvant imatinib treatment, R1 resection still remained unfavorable (HR 1.758, 95% CI 1.338--2.310; I^2^ = 11.3%, P value = 0.343). These results indicated that adjuvant imatinib treatment could reduce the risk of recurrence for primary GIST patients who received R1 resection, clearly indicating a need for adjuvant treatment in this group. Although there is no evidence that re-excision could benefit the patients with R1 resection, re-excision is acceptable only if the original site of lesion can be found, and major functional sequelae are not foreseen[@b11]. Based on the results of this meta-analysis, adjuvant imatinib treatment is proved to be effective for GIST patients with R1 resection. Therefore, we suggest that adjuvant imatinib treatment combined with re-excision might be a standard approach for patients with R1 resection, and adjuvant imatinib treatment alone could also be sufficient for patients who are not suitable to undergo re-excision. The final decision should be carefully made by the multidisciplinary care team taking into account of possible risks and benefits.

The level of evidence achieved in this meta-analysis was assessed by the GRADE approach ([Table 5](#t5){ref-type="table"}). The critical outcomes: the quality of DFS was "moderate" and the quality of OS was "low". The important outcome: the quality of recurrence rate was "low". The levels of these outcomes were confined due to the limited evidence derived from observational studies. In addition, the quality of recurrence rate and OS was degraded due to the observational studies. Therefore, the quality of evidence for R1 resection as an unfavorable prognostic factor of GISTs is acceptable.

Some limitations of this meta-analysis should be discussed. The analysis of the included studies reporting the status of surgical margins needs to account for some confounding variables. The rate of R1 resection seemed to be associated with both tumor size and recurrent risk[@b14][@b37]. Given that GISTs with "intermediate" or "high" risk are easier to obtain microscopically positive margins, it is difficult to distinguish whether surgical margin or tumor grade is the major factor of recurrence risk for the patients with R1 resection. It is possible that surgical margin and tumor grade have a collinear relation in the analysis of tumor recurrence. To clarify this assumption, further studies with large sample of patients who received R1 resection are needed and analysis of the relevance between status of surgical margins and tumor grade should also performed in those studies. Unfortunately, there is only one study[@b14] reporting the risk factors associated with and R1 resection among the studies included in this meta-analysis. Besides, this study proves that adjuvant imatinib treatment is effective in reducing the recurrence rate by the analysis of all patients with R1 resection. However, whether adjuvant imatinib treatment is essential for patients with R1 resection who are "very low" or "low" grade cannot be determined from this meta-analysis.

In conclusion, this meta-analysis revealed that a microscopically positive margin could significantly impact the disease-free survival, but had no influence on overall survival. In addition, adjuvant imatinib treatment could reduce the risk of recurrence for primary GIST patients who received R1 resection. Our results validated the goal of surgery with a negative microscopic margin and determined the management of R1 resection for GISTs.

Methods
=======

Literature search
-----------------

Two investigators (XZ and BJ) performed a systematic literature search in PubMed, EMBASE, Cochrane Library and Web of Science databases (last updated on July 15, 2015), using combinations of the following terms: "gastrointestinal stromal tumors", "GIST", and "margins". Disagreements were resolved through consensus with a third investigator (LM). Reports in English were eligible for inclusion. The bibliographies cited in selected articles were also examined to identify other relevant studies. Conference abstracts were excluded due to the insufficient data reported. All studies were carefully evaluated to identify duplicate data.

Inclusion criteria
------------------

The following criteria were used for the study selection: (1) Participants (P): All patients were diagnosed as primary GIST using pathology and immunohistochemistry. (2) Interventions (I) and comparisons (C): Comparing the prognosis of R1 resection versus R0 resection. (3) Outcomes (O): Disease-free survival (DFS), Overall survival (OS), and microscopically positive margin rate (MPMR). (4) Study design (S): retrospective or prospective study. (5) Sufficient information allowing for estimation of hazard ratios (HRs) and 95% confidence intervals (CIs).

Qualitative assessment
----------------------

Quality assessment was performed in each of the acceptable studies in duplicate by independent reviewers (XZ and BJ) using the Newcastle-Ottawa Quality Assessment Scale for cohort studies. Discrepancies were resolved by a third reviewer (LM).

Data extraction
---------------

Two reviewers (XF and JY) independently extracted the required information from all primary studies. If HRs or their 95% CIs were not directly reported in the included studies, they were estimated according to the available survival data using a method reported by Tierney *et al.*[@b38]. If the trial results were reported in multiple publications, we extracted the data from the article with the strictest methodology and the most complete data.

Statistical analysis
--------------------

We used the PRISMA checklist[@b39] as protocol of the meta-analysis and followed the guideline ([Table S2](#S1){ref-type="supplementary-material"}). For the pooled analysis of the survival data, HRs and their 95% CIs were used. The point estimate of the HR was considered statistically significant at the p \< 0.05 level if the 95% CI did not include the value "1".

Heterogeneity assumption was checked by the chi-square-based Q-test. A *p*-value \>0.10 for the Q-test indicates a lack of heterogeneity among studies. We also quantified the effect of heterogeneity using I^2^ test. I^2^ values of \<25% may be considered "low," values of about 50% may be considered "moderate" and values of \>75% may be considered "high"[@b40]. Both fixed-effects (Mantel--Haenszel method) and random-effects (DerSimonian--Laird method) models were used to estimate the pooled HRs/ORs. Given the inherent between-study heterogeneity, the random-effects model was chosen. To explore the heterogeneity between studies better, meta-regression analysis and subgroup analysis were performed. To explore the dynamic trends as studies accumulated over time, cumulative meta-analysis was performed by date of publication. Sensitivity analyses were conducted to validate whether modification of inclusion criteria affected the results. Potential publication bias was estimated by the funnel plot and Egger's linear regression test. All analyses were carried out using STATA version 10.0 (Stata Corporation, College Station, TX). Two-sided *p* \< 0.05 was considered statistically significant.

Grading the quality of evidence
-------------------------------

The GRADE approach was used to interpret and validate the results[@b41]. The GRADEprofiler version 3.6 was used to create the evidence profile. For each outcome, we graded the quality of the studies at four levels as "very low", "low", "moderate" and "high" on the basis of risk of bias, inconsistency, indirectness, imprecision and publication bias.
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###### Main characteristics of the included studies.

  Study                 Year   Sample size   R0 resection   Recurrence in R0 resection   R1 resection   Recurrence in R1 resection   Adjuvant imatinib treatment   Survival analysis   Outcomes   Follow-up (median, range)   Quality score
  -------------------- ------ ------------- -------------- ---------------------------- -------------- ---------------------------- ----------------------------- ------------------- ---------- --------------------------- ---------------
  Cananzi *et al.*      2014       92             86                    31                    6                     2                            Yes                 Kaplan--Meier     DFS, OS        41, 2--145 months             7
  Jakob *et al.*        2013       36             24                    3                     12                    4                            Yes                 Kaplan--Meier     DFS, OS        41, 3--110 months             7
  McCarter *et al.*     2012       817           745                   204                    72                    26                           Yes                 Kaplan--Meier       DFS              49 months                 8
  Kim *et al.*          2012       136           122                    5                     14                    0                            No                  Kaplan--Meier       DFS          29, 3--106 months             7
  Huang *et al.*        2012       85             82                    NR                    3                     NR                           Yes                 Kaplan--Meier     DFS, OS        41, 3--100 months             7
  Catena *et al.*       2012       151           132                    71                    19                    6                            No                 Cox regression       DFS         101, 11--132 months            7
  Nikfarjam *et al.*    2008       40             35                    NR                    5                     NR                           Yes                 Kaplan--Meier     DFS, OS        24, 1--74 months              7
  Gouveia *et al.*      2008       96             78                    7                     18                    5                            No                 Cox regression     DFS, OS        42, 1--206 months             7
  Rutkowski *et al.*    2007       328           253                   151                    75                    29                           No                 Cox regression       DFS          31, 4--292 months             7
  Wu *et al.*           2006       85             81                    NR                    4                     NR                           No                 Cox regression     DFS, OS        33, 5--202 months             7
  Pierie *et al.*       2001       39             35                    13                    4                     3                            No                 Cox regression     DFS, OS        38, 1--159 months             7
  DeMatteo *et al.*     2000       80             65                    NR                    15                    NR                           No                  Kaplan--Meier        OS          24, 1--175 months             7

DFS, disease-free survival; OS, overall survival; NR, not reported.

###### Meta-regression and stratified analysis of pooled odds ratios of R1 resection for tumor recurrence.

  Stratified analysis            No. of studies   No. of patients    Pooled OR (95% CI)       Heterogeneity       Meta-regression                       
  ----------------------------- ---------------- ----------------- ---------------------- ---------------------- ----------------- ----------- -------- -------
  Overall                              9               1695         0.891 (0.653--1.215)   1.203 (0.632--2.287)        66.2%        0.003^\*^               
  Adjuvant imatinib treatment                                                                                                                   63.98%   0.592
  Yes                                  3                592         1.474 (0.849--2.558)   1.477 (0.846--2.579)        0.0%           0.513                 
  No                                   6               1103         0.715 (0.490--1.041)   1.092 (0.445--2.683)        72.4%        0.003^\*^               

OR, odds ratios; CI, confidence interval; Fixed, fixed-effects model; Random, random-effects model; ^\*^indicating heterogeneity.

###### Meta-regression and stratified analysis of pooled hazard ratios of R1 resection for disease-free survival.

  Stratified analysis            No. of studies   No. of patients    Pooled HR (95% CI)       Heterogeneity       Meta-regression                       
  ----------------------------- ---------------- ----------------- ---------------------- ---------------------- ----------------- ----------- -------- -------
  Overall                              12              1905         1.567 (1.246--1.969)   1.596 (1.128--2.258)        37.5%        0.091^\*^               
  Adjuvant imatinib treatment                                                                                                                   34.47%   0.252
  Yes                                  5                717         1.193 (0.784--1.815)   1.308 (0.583--2.935)        53.2%        0.074^\*^               
  No                                   7               1188         1.758 (1.338--2.310)   1.785 (1.298--2.456)        11.3%          0.343                 
  Sample size                                                                                                                                   40.36%   0.523
  \>100                                5               1432         1.495 (1.161--1.924)   1.472 (1.024--2.116)        39.6%          0.157                 
  \<100                                7                473         1.940 (1.132--3.325)   1.897 (0.922--3.902)        41.5%          0.115                 

HR, hazard ratios; CI, confidence interval; Fixed, fixed-effects model; Random, random-effects model; ^\*^indicating heterogeneity.

###### Meta-regression and stratified analysis of pooled hazard ratios of R1 resection for overall survival.

  Stratified analysis            No. of studies   No. of patients    Pooled HR (95% CI)       Heterogeneity       Meta-regression                       
  ----------------------------- ---------------- ----------------- ---------------------- ---------------------- ----------------- ----------- -------- -------
  Overall                              8                553         1.283 (0.770--2.138)   1.430 (0.608--3.363)        60.8%        0.013^\*^               
  Adjuvant imatinib treatment                                                                                                                   58.96%   0.667
  Yes                                  4                253         0.651 (0.262--1.616)   1.232 (0.185--8.204)        73.8%        0.010^\*^               
  No                                   4                300         1.755 (0.947--3.254)   1.769 (0.926--3.380)        8.4%           0.351                 

HR, hazard ratios; CI, confidence interval; Fixed, fixed-effects model; Random, random-effects model; ^\*^indicating heterogeneity.

###### GRADE evidence profile.

  Quality assessment                                    No of patients               Effect                         Quality                       Importance                                                                                                                                                                                                                         
  ------------------------------------------------- ----------------------- ------------------------- ------------------------------------ ------------------------- ------------------------ -------------------------------------------------------- ---------------- ------------------ --------------------------- ---------------------------------------------- -------------- -----------
  Recurrence rate (follow-up 8.8--24 years)                                                                                                                                                                                                                                                                                                                                          
  9                                                  observational studies   no serious risk of bias   serious[1](#t5-fn1){ref-type="fn"}   no serious indirectness   no serious imprecision   increased effect for RR \~1[2](#t5-fn2){ref-type="fn"}   75/220 (34.1%)   485/1475 (32.9%)   OR 1.203 (0.632 to 2.287)   42 more per 1000 (from 92 fewer to 200 more)     ⊕⊕ΟΟ Low     Critical
  Disease-free survival (follow-up 6.1--24 years)                                                                                                                                                                                                                                                                                                                                    
  12                                                 observational studies   no serious risk of bias        no serious inconsistency        no serious indirectness   no serious imprecision   increased effect for RR \~1[2](#t5-fn2){ref-type="fn"}        232               1673         HR 1.596 (1.128 to 2.258)                       ---                        ⊕⊕Ο Moderate   Critical
  Overall survival (follow-up 6.1--17 years)                                                                                                                                                                                                                                                                                                                                         
  8                                                  observational studies   no serious risk of bias   serious[1](#t5-fn1){ref-type="fn"}   no serious indirectness   no serious imprecision   increased effect for RR \~1[2](#t5-fn2){ref-type="fn"}         67               486          HR 1.430 (0.068 to 3.363)                       ---                          ⊕⊕ΟΟ Low     Important

^1^The statistical test for heterogeneity showed a low P value.

^2^Numerous specimen processing variables when assessing positive margins might influence the rate of positive margins.

[^1]: These authors contributed equally to this work.
